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a  b  s  t  r  a  c  t
Introduction: Multiple sclerosis (MS) and neuromyelitis optica (NMO) are demyelinating dis-
eases  of the central nervous system. Autoimmunity in patients with demyelinating disease
and in their families has been broadly investigated and discussed. Recent studies show a
higher incidence of rheumatic autoimmune diseases among adult patients with MS  or NMO
and  their families, but there are no studies in the pediatric population.
Objective: To evaluate an association of MS and NMO with autoimmune rheumatic diseases
in  pediatric patients.
Method: 22 patients younger than 21 years old with MS or NMO  diagnosed before the age of
18  years were evaluated regarding epidemiological data, clinical presentation, association
with autoimmune diseases, family history of autoimmune diseases, laboratory ﬁndings,
imaging studies and presence of auto-antibodies.
Results: Among the patients studied, there was a prevalence of females (68.1%). The mean
age of symptoms onset was 8 years and 9 months and the mean current age was 16 years
and  4 months. Two patients (9%) had a history of associated autoimmune rheumatic disease:
one case of juvenile dermatomyositis in a patient with NMO and another of systemic lupus
erythematosus in a patient with MS. Three patients (13%) had a family history of autoim-
munity  in ﬁrst-degree relatives. Antinuclear antibody was found positive in 80% of patients
with NMO and 52% of patients with MS. About 15% of antinuclear antibody-positive patients
were diagnosed with rheumatologic autoimmune diseases.
Conclusion: Among patients with demyelinating diseases diagnosed in childhood included
in  this study there was a high frequency of antinuclear antibody positivity but a lower asso-
ciation with rheumatologic autoimmune diseases than that observed in studies conductedPlease cite this article in press as: Amorim AL, et al. Association between demyelinating disease and autoimmune rheumatic disease in a
pediatric population. Rev Bras Reumatol. 2016. http://dx.doi.org/10.1016/j.rbre.2016.09.016
in  adults.
© 2016 Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ade  Federal de São Paulo, São Paulo, SP, Brazil.
∗ Corresponding author.
E-mail: amorim.analuiza@gmail.com (A.L. Amorim).
ttp://dx.doi.org/10.1016/j.rbre.2016.09.016
255-5021/© 2016 Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
icenses/by-nc-nd/4.0/).
ARTICLE IN PRESSRBRE-335; No. of Pages 5
2  r e v b r a s r e u m a t o l . 2 0 1 6;x  x x(x x):xxx–xxx
Associac¸ão  entre  doenc¸a desmielinizante  e  doenc¸a reumática  autoimune






r  e  s  u  m  o
Introduc¸ão: Esclerose Múltipla (EM) e Neuromielite Óptica (NMO) são doenc¸as desmielin-
izantes do sistema nervoso central. A autoimunidade entre pacientes com doenc¸as
desmielinizantes e seus familiares tem sido amplamente investigada e discutida. Estudos
recentes demonstram maior incidência de doenc¸as reumáticas autoimunes entre pacientes
adultos com EM e NMO e seus familiares, mas não há estudos na populac¸ão pediátrica.
Objetivo: Avaliar a associac¸ão de EM e NMO com doenc¸as reumáticas autoimunes em
pacientes pediátricos.
Método: Foram incluídos 22 pacientes menores de 21 anos com diagnóstico de EM ou
NMO antes dos 18 anos de idade e avaliados dados epidemiológicos, clínicos, associac¸ão
com  doenc¸as autoimunes, história familiar de doenc¸as autoimunes, exames laboratoriais,
exames de imagem e presenc¸a de auto-anticorpos.
Resultados: Entre os pacientes estudados, houve prevalência do sexo feminino (68,1%). A
média de idade de início dos sintomas foi de 8 anos e 9 meses e a média de idade dos
pacientes na avaliac¸ão foi 16 anos e 4 meses. Dois pacientes (9%) apresentaram doenc¸a
reumática autoimune associada, sendo um caso de dermatomiosite juvenil em paciente
com  NMO e outro de lúpus eritematoso sistêmico juvenil em paciente com EM.  Três
pacientes (13%) apresentaram história familiar de autoimunidade em parentes de primeiro
grau. Anticorpo antinuclear (ANA) positivo foi encontrado em 80% dos pacientes com NMO e
em  52% dos pacientes com EM. Cerca de 15% dos pacientes com ANA positivo apresentaram
diagnóstico deﬁnitivo de doenc¸a autoimune reumática associada.
Conclusão: Entre os pacientes com doenc¸as desmielinizantes diagnosticadas durante a
infância incluídos nesta pesquisa houve uma alta frequência de ANA positivo, mas  uma
menor taxa de associac¸ão com doenc¸as reumáticas autoimunes que a encontrada em tra-
balhos conduzidos em adultos.
© 2016 Elsevier Editora Ltda. Este e´ um artigo Open Access sob uma licenc¸a CCIntroduction
The term demyelinating disorder refers to a group of diseases
that have in common the loss of the myelin sheath, with a
relative axonal preservation. Among the various categories,
we  highlight those of inﬂammatory origin, in particular, mul-
tiple sclerosis (MS), the most disabling neurological disease
in young adults, and neuromyelitis optica (NMO). Clinical
and pathological aspects of these conditions lead one to
believe that these are inﬂammatory autoimmune diseases,
which lead to a progressive deterioration of multiple body
functions.1–4
MS may involve any part of the CNS at different times
of its progression. The most common early symptoms are
paresis of one or more  members, pyramidal signs (spasticity,
hyperreﬂexia, Babinski sign, and clonus), ataxia, dysarthria,
paresthesias, fecal or urinary incontinence or retention, or
sexual dysfunction.5
NMO,  or Devic disease, is characterized by the production
of antibodies against the blood–brain barrier. The ﬁrst symp-
toms occur between the 3rd and 4th decades of life, in the
form of optic neuritis and/or myelitis with longitudinal exten-
sion. Optic neuritis is manifested with an acute bilateral lossPlease cite this article in press as: Amorim AL, et al. Association betwe
pediatric population. Rev Bras Reumatol. 2016. http://dx.doi.org/10.1016/j.
of visual acuity, with partial recovery. Myelitis is characterized
by bilateral motor symptoms, with signiﬁcant loss of strength,
sensory changes and partial recovery after outbreaks.6BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
The autoimmunity that surrounds patients with demyeli-
nating disease and their family members has been widely
investigated and discussed. Recent studies show that patients
with MS  and NMO, as well as their families, are at greater
risk of presenting, at some point, an associated diagnosis of
an autoimmune rheumatic disease. However, none of these
studies was directed to the pediatric population.7,8
The aim of this study was to evaluate the association of MS
or NMO with autoimmune rheumatic diseases in a pediatric
population and their ﬁrst-degree relatives.
Patients  and  methods
In this retrospective cross-sectional study we  included all
patients with a current age up to 21 years, diagnosed with
MS according to McDonald criteria, or with NMO  according to
the 2006 revised criteria, monitored in Demyelinating Disease
Unit of the Department of Neurology and Neurosurgery, and
in the Pediatric Rheumatology Unit of the Department of Pedi-
atrics, Unifesp/EPM. The diagnosis of juvenile systemic lupus
erythematosus (JSLE) and juvenile dermatomyositis (JDM) was
established in accordance with published criteria.6,9–11 All
patients were under the age of 18 at diagnosis of demyelinat-en demyelinating disease and autoimmune rheumatic disease in a
rbre.2016.09.016
ing disease or autoimmune rheumatic disease.
The following information was collected from the clini-
cal records: demographics, current age, age at the onset of
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Table 1 – Demographic characteristics of the study
population.
MS NMO Total
n = 17 n  = 5 n = 22
Female gender 10 (58.8) 5 (100) 15 (68.2)
Current age (months) 223 235 224
Age at the onset of
symptoms (months)
150 120 132




























Four patients (23.5%) with MS were treated with glati-MS, multiple sclerosis; NMO, neuromyelitis optica.
Results are expressed as n (%) and median (range).
ymptoms, and disease duration; signs and symptoms of
emyelinating disease, recurrence history, number of out-
reaks and intervals between these outbreaks; autoimmune
iseases associated; family history of autoimmune disease;
aboratory tests and presence of antinuclear antibody (ANA),
heumatoid factor (RF), extractable nuclear antigen (ENA)
ntibodies, anti-aquaporin, anti-cardiolipin and anti-DNA;
erebrospinal ﬂuid (CSF) analysis, and imaging tests such as
rain magnetic resonance imaging (MRI) l and MRI  of the
pinal column.
The demographic and clinical characteristics were
escribed in absolute and relative frequencies, median,
nd minimum and maximum values, according to the nature
f the variables studied.
esults
wenty-two patients with a diagnosis of demyelinating dis-
ase were selected: 17 patients with MS  (77.3%) and ﬁve
atients with NMO  (22.7%). Table 1 summarizes the demo-
raphic characteristics of these patients.
The predominant complaints of patients with MS were
ight impairment (41%), brainstem impairment (41%), and
yramidal motor impairment (35%). All patients with NMO
howed sight impairment at some point in the progression of
he disease. Other frequent complaints were pyramidal motor
mpairment (60%), sensory impairment (40%), and sphincter
mpairment (40%) (Table 2). Table 2 describes the clinical char-
cteristics of patients with demyelinating diseases.Please cite this article in press as: Amorim AL, et al. Association betwee
pediatric population. Rev Bras Reumatol. 2016. http://dx.doi.org/10.1016/j.
Fourteen patients with MS  had recurrences with an aver-
ge of 2.5 outbreaks per patient, with a minimum interval of
ne month and a maximum interval of 108 months between
Table 2 – Clinical characteristics of the study population.
Motor impairment (tetraparesis/hemiparesis/paraparesis)
Cerebellar impairment (dysmetry and gait ataxia) 
Sensory impairment (superﬁcial and deep tactile hypoesthesia/painful hy
Visual impairment (decrease in visual acuity and afferent pupillary defect
Brainstem impairment (diplopia, nystagmus) 
Sphincter impairment (bladder/anal) 
MS, multiple sclerosis; NMO, neuromyelitis optica.
Results are expressed as n (%). 6;x  x x(x x):xxx–xxx 3
outbreaks. All patients with NMO had a history of recurrence,
with a mean of three outbreaks per patient, with a minimum
interval of two months and a maximum interval of 29 months
between outbreaks.
Among the patients included in this study, only two  (9%)
had a history of association with an autoimmune rheumatic
disease. The ﬁrst patient had a previous diagnosis of MS,  and
about a year after the ﬁrst outbreak, this patient evolved with
clinical and laboratory ﬁndings compatible with JSLE. The sec-
ond patient had a diagnosis of JDM, evolving with a diagnosis
of NMO about ten years after the onset of symptoms of the
autoimmune disease.
Only three (13%) patients had a family history of autoim-
munity in ﬁrst-degree relatives. Two patients with MS  (one of
them diagnosed with JSLE associated with the demyelinating
disease) had a family history of systemic lupus erythemato-
sus. A patient with a diagnosis of NMO had a family history of
rheumatoid arthritis.
Among those patients with MS, nine (53%) were ANA-
positive subjects, including the patient with JSLE. There was
a predominance of a nuclear ﬁne speckled pattern (88%). The
patient with an associated diagnosis of JSLE also tested pos-
itive for IgM anti-cardiolipin and anti-nucleosome. Among
patients with NMO, four (80%) had a positive ANA, including
the patient with JDM. There was a predominance of a nuclear
ﬁne speckled pattern (75%). The patient with an associated
diagnosis of JDM was also positive for anti-cardiolipin IgM. On
a subsequent examination, the result for this antibody was
negative. Altogether, 15% of ANA-positive patients showed a
conclusive diagnosis of autoimmune rheumatic disease asso-
ciated with a demyelinating disease.
Three of the patients diagnosed with NMO  (60%) were pos-
itive for anti-aquaporin. Table 3 summarizes the presence of
autoantibodies in the study population.
No anti-ENA antibodies, anti-DNA antibodies, or rheuma-
toid factor were found in these patients. None of the patients
in this study had any cytopenia (anemia, leukopenia, throm-
bocytopenia), a decrease in complement, or kidney function
changes.
Only patients diagnosed with MS were subjected to a lum-
bar puncture. Of these patients, six (35.3%) had oligoclonal
bands in cerebrospinal ﬂuid.n demyelinating disease and autoimmune rheumatic disease in a
rbre.2016.09.016
ramer, and nine (52.9%) patients received treatment with
interferon beta. Other drugs associated were prednisone (5%)
and immunoglobulin (5%). The patient diagnosed with JSLE
MS NMO Total
n = 17 n = 5 n = 22
6 (35.3) 3 (60) 9 (40.1)
3 (17.6) 0 3 (13.6)
poesthesia) 4 (23.5) 2 (40) 6 (27.3)
) 7 (41.2) 5 (100) 12 (54.5)
7 (41.2) 0 7 (31.8)
1 (5.9) 2 (40) 3 (13.6)
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Table 3 – Presence of autoantibodies in the study
population.
MS NMO Total
n = 17 n = 5 n = 22
ANA 9 (52.9) 4 (80) 13 (59.1)
Pattern NFS 8 (88.9) 3 (75) 11 (84.6)
Other patterns 1 (11.1) 1 (25) 2 (15.4)
Dilution 1:160 3 (33) 1 (25) 4 (30.8)
1:320 3 (33) 2 (50) 5 (38.5)
1:640 1 (11) 0 1 (7.7)
1:1280 2 (22) 1 (25) 3 (23.1)
aCL IgM 1 (5.9) 1 (20) 2 (9.1)
IgG 0 0 0
Other Anti-aquaporin a 3 (60) a
MS, multiple sclerosis; NMO, neuromyelitis optica; ANA, antin-
uclear antibody; NFS, nuclear ﬁne speckled pattern; aCL, anti-
cardiolipin. Results are expressed as n (%).
a The anti-aquaporin antibody was evaluated only in patients witha diagnosis of NMO.
was also treated with acetylsalicylic acid, hydroxychloroquine,
and azathioprine, as well as with intravenous methylpred-
nisolone and cyclophosphamide. All NMO  patients received
treatment with prednisone and azathioprine, and one patient
was treated with intravenous immunoglobulin. The patient
diagnosed with an associated JDM also received treatment
with methotrexate.
Patients diagnosed with MS-JSLE and NMO-JDM had several
episodes of outbreaks and remissions throughout their pro-
gression and currently are in remission without neurological
sequelae.
Discussion
Different studies have shown an association between demyeli-
nating diseases and other autoimmune diseases.8 The results
of a recent systematic review point to systemic lupus ery-
thematosus (SLE) and rheumatoid arthritis as the rheumatic
autoimmune diseases most often associated with MS.8
In 2000, a case–control study compared MS patients ver-
sus controls without demyelinating diseases, mostly adults,
regarding the occurrence of autoimmune diseases, which
included autoimmune thyroiditis, autoimmune gastritis,
Addison’s disease, rheumatoid arthritis, pemphigus vulgaris,
scleroderma, primary biliary cirrhosis, SLE, and ankylosing
spondylitis. Patients with MS  had a higher prevalence of these
conditions (20%) compared to controls without MS (13%) and
their ﬁrst-degree relatives (45% vs. 27%, respectively).7 In 2006
a case–control study found similar results that further pointed
to the importance of HLA-DR genes in the determination of
autoimmunity involving MS  patients and their families.12
A study on patients (mostly adults) with NMO also
showed that about one-third of patients had a diagnosis of
another autoimmune disease, such as Sjogren’s syndrome,
primary sclerosing cholangitis, and immune thrombocy-Please cite this article in press as: Amorim AL, et al. Association betwe
pediatric population. Rev Bras Reumatol. 2016. http://dx.doi.org/10.1016/j.
topenic purpura.13
On the other hand, a retrospective cohort showed no
increased risk of autoimmune rheumatic diseases in patients 1 6;x  x x(x x):xxx–xxx
with MS  (RR: 0.9; CI: 0.7–1.03), unlike their relatives, who  were
at increased risk for such diseases (RR: 1.2; CI: 1.1–1.4).14 These
ﬁndings may be related to a possible bias and to the use of
different diagnostic criteria for the different autoimmune dis-
eases evaluated.14
Two patients (9%) with MS or NMO included in this
study had autoimmune rheumatic diseases: JSLE and JDM,
respectively. Although SLE has been described in association
with demyelinating diseases, in our review of the literature
we found only two publications relating these diseases to
dermatomyositis.15,16 The ﬁrst report refers to a male adult
with a previous diagnosis of MS  that, after treatment with
interferon beta-1a, came to suffer the typical rash of der-
matomyositis (Gottron’s papules and heliotrope rash) and
proximal muscle weakness with a skin biopsy compatible
with the diagnosis.15 The second publication consists of a
series of cases of patients with NMO with its onset in child-
hood and adolescence, in which one of the patients had an
associated diagnosis of JDM. In this publication, neither the
clinical course nor the treatment received by this patient was
detailed; moreover, the family history of autoimmune diseases
in patients with NMO  has not been evaluated.16
The neurologic manifestations of SLE patients can mimic
the changes found in patients with MS and NMO, especially
in those periods when the disease is more  active. Transverse
myelitis, for example, although rare, has been described sev-
eral times as a neurological manifestation of SLE patients, with
or without optic neuritis. In these patients, the differentiation
between SLE activity, or coexistence of MS  or NMO,  may be
complex.17
Szmyrka-Kaczmarek et al. describe in their case–control
study the highest prevalence of ANA and anti-phospholipid
antibodies in patients with MS – without, however, any corre-
lation with symptoms suggestive of autoimmune rheumatic
diseases or thromboembolic events.18 In the same study,
it was possible to correlate the autoantibodies to certain
patterns of clinical presentation of MS. Thus, ANA-positive
patients, mainly with high titles, suffer from a disease of
shorter duration, with little progression to disability. On the
other hand, the presence of anti-2 glycoprotein I was asso-
ciated with diseases of a more  dragged course, with greater
limitations.18
In their study, Hilario et al. found ANA positivity in 12.6% of
healthy children and in 36.2% of children with several autoim-
mune rheumatic diseases.19 Studies show that the positivity
of ANA in MS patients can vary from 20% to 60%; on the
other hand, in patients with NMO this positivity approaches
45%.20,18,21 The positivity of ANA in patients with demyeli-
nating diseases included in this study was about 59%, of
which 15% (2 patients) had a ﬁnal diagnosis of an associated
autoimmune rheumatic disease. It is suggested, therefore,
that patients with demyelinating diseases and with ANA posi-
tivity receive a more  detailed complementary investigation to
exclude the possibility of associated autoimmune disorders.
In short, among patients with demyelinating diseases diag-
nosed in infancy included in this study, we  found a high
frequency of ANA positivity, but a lower rate of associationen demyelinating disease and autoimmune rheumatic disease in a
rbre.2016.09.016
with autoimmune rheumatic diseases than that found in stud-
ies conducted on adults, although signiﬁcant in the population
of this study.
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